<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A feasibility study was undertaken to identify patient-specific primers (PSPs) from childhood non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) specimens to detect <z:e sem="disease" ids="C0242596" disease_type="Neoplastic Process" abbrv="MRD">minimal residual disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Eleven <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> specimens were amplified using immunoglobulin heavy chain and T-cell receptor primers to identify PSPs, which were then used to evaluate staging/follow-up specimens </plain></SENT>
<SENT sid="2" pm="."><plain>Disease was detected in 19 of 21 staging and 16 of 17 follow-up specimens </plain></SENT>
<SENT sid="3" pm="."><plain>Among seven patients in remission by 1 month, PSPs identified <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> in follow-up specimens </plain></SENT>
<SENT sid="4" pm="."><plain>This study demonstrated the feasibility of PSPs to identify disease in staging and follow-up specimens, which could be used to develop strategies for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> analysis in a larger setting </plain></SENT>
</text></document>